NCT00348127

Brief Summary

To assess how well and safe is Neurovision technology in improving the vision of people with low myopia in Singapore

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Mar 2003

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2003

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2004

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2004

Completed
1.8 years until next milestone

First Submitted

Initial submission to the registry

July 3, 2006

Completed
1 day until next milestone

First Posted

Study publicly available on registry

July 4, 2006

Completed
Last Updated

June 24, 2010

Status Verified

January 1, 2010

Enrollment Period

1.6 years

First QC Date

July 3, 2006

Last Update Submit

June 23, 2010

Conditions

Keywords

NeurovisionMyopia Therapy

Outcome Measures

Primary Outcomes (7)

  • Manifest Subjective and Objective refraction

  • Cycloplegic Objective refraction

  • Accommodation amplitude

  • Distance visual acuity (Uncorrected Visual Acuity - UCVA, and BCVA)

  • Near visual acuity

  • Contrast sensitivity (corrected and uncorrected)

  • Visual Evoked Potential (VEP) and Multifocal VEP

Interventions

Eligibility Criteria

Age15 Years - 55 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)

You may qualify if:

  • The subject's cycloplegic spherical equivalence in the worst eye does not exceed -1.5 DS and the astigmatism does not exceed 0.50 DC.
  • The subject's refractive status is stable, with no increase beyond 0.5D in sphere or cylinder over the last six months.
  • The subject's age is between 17-55 years.
  • The subject's uncorrected visual acuity 0.7 LogMar
  • The subject's best corrected visual acuity 0.05 LogMar
  • The subject is cognitively intact and is able to follow multiple step instructions.
  • The subject is able and willing to attend all study sessions and visits at the required frequency:
  • The total number of treatments is individual, approximately 30.
  • The required pace for the treatment sessions is at least 3 sessions per week.
  • No foreseen interruptions longer than 2 weeks during the treatment course.
  • Subject (or subject's parent/legal guardian if subject is less than 21 years of age at study entry) agrees to sign the Informed Consent Form (See Appendix D)

You may not qualify if:

  • The subject suffers from any other eye disease(s) or other causes for the reduced visual acuity, aside from myopia and/or astigmatism.
  • The subject suffers from myopia-related visual complications resulting in visual loss, including myopic macular degeneration, myopic cataract and previous or pre-existing myopic retinal detachment.
  • The subject is suffering from Diabetes Mellitus.
  • The subject has previously undergone a refractive surgery procedure in either eye.
  • The subject is or may be pregnant.
  • The subject has an activity limitation due to medical disorders (including migraines, seizure disorders, etc.), medications, or emotional status that might potentially impair the subject's ability to perform the treatment.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Singapore Eye Research Institute

Singapore, 168751, Singapore

Location

Related Publications (8)

  • Polat U, Ma-Naim T, Belkin M, Sagi D. Improving vision in adult amblyopia by perceptual learning. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6692-7. doi: 10.1073/pnas.0401200101. Epub 2004 Apr 19.

    PMID: 15096608BACKGROUND
  • Polat U, Mizobe K, Pettet MW, Kasamatsu T, Norcia AM. Collinear stimuli regulate visual responses depending on cell's contrast threshold. Nature. 1998 Feb 5;391(6667):580-4. doi: 10.1038/35372.

    PMID: 9468134BACKGROUND
  • Levi DM, Polat U, Hu YS. Improvement in Vernier acuity in adults with amblyopia. Practice makes better. Invest Ophthalmol Vis Sci. 1997 Jul;38(8):1493-510.

    PMID: 9224277BACKGROUND
  • Polat U, Norcia AM. Neurophysiological evidence for contrast dependent long-range facilitation and suppression in the human visual cortex. Vision Res. 1996 Jul;36(14):2099-109. doi: 10.1016/0042-6989(95)00281-2.

    PMID: 8776476BACKGROUND
  • Sagi D, Tanne D. Perceptual learning: learning to see. Curr Opin Neurobiol. 1994 Apr;4(2):195-9. doi: 10.1016/0959-4388(94)90072-8.

    PMID: 8038576BACKGROUND
  • Polat U, Sagi D. Spatial interactions in human vision: from near to far via experience-dependent cascades of connections. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1206-9. doi: 10.1073/pnas.91.4.1206.

    PMID: 8108388BACKGROUND
  • Polat U, Sagi D. Lateral interactions between spatial channels: suppression and facilitation revealed by lateral masking experiments. Vision Res. 1993 May;33(7):993-9. doi: 10.1016/0042-6989(93)90081-7.

    PMID: 8506641BACKGROUND
  • Levi DM, Polat U. Neural plasticity in adults with amblyopia. Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6830-4. doi: 10.1073/pnas.93.13.6830.

    PMID: 8692904BACKGROUND

Related Links

MeSH Terms

Conditions

Myopia

Condition Hierarchy (Ancestors)

Refractive ErrorsEye Diseases

Study Officials

  • Donald Tan, FRCS

    Singapore Eye Research Institute

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV

Study Record Dates

First Submitted

July 3, 2006

First Posted

July 4, 2006

Study Start

March 1, 2003

Primary Completion

October 1, 2004

Study Completion

October 1, 2004

Last Updated

June 24, 2010

Record last verified: 2010-01

Locations